Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>✅ IPO PROPHET RATING: 8.1/10 🏦 Deal Quality &amp; Underwriters: 9/10 MiniMed Group is set to list on the Nasdaq under the symbol MMED, offering 28.0 million shares at $25.00 to $28.00 per share, implying gross proceeds of about $742 million at the midpoint.</li><li>The offering is led by a strong global syndicate and anchored in a business with recurring revenue potential and durable demand characteristics tied to chronic care management.</li><li>MiniMed’s syndicate — led by Goldman Sachs, Bank of America, Citi, and Morgan Stanley — remains among the most credible in the current IPO landscape.</li></ul>

✅ IPO PROPHET RATING: 8.1/10 🏦 Deal Quality &amp; Underwriters: 9/10 MiniMed Group is set to list on the Nasdaq under the symbol MMED, offering 28.0 million shares at $25.00 to $28.00 per share, implying gross proceeds of about $742 million at the midpoint.The offering is led by a strong global syndicate and anchored in a business with recurring revenue potential and durable demand characteristics tied to chronic care management.MiniMed’s syndicate — led by Goldman Sachs, Bank of America, Citi, and Morgan Stanley — remains among the most credible in the current IPO landscape.

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>MiniMed, spun-off diabetes business of Medtronic, has filed for an IPO. The company intends to use part of the proceeds from this offering to repay intercompany debt owed to Medtronic.</li>
<li>Despite double-digit revenue growth, MiniMed is currently reporting loss. The company aims to drive profitability by generating more revenue per customer than its competitors using its comprehensive offerings.</li>
<li>Commercially and operationally, MiniMed’s scaled global infrastructure creates a significant barrier to entry. Moreover, robust global user base of 640K entails recurring revenue generation opportunity through selling compatible consumable products.</li>
</ul>


MiniMed, spun-off diabetes business of Medtronic, has filed for an IPO. The company intends to use part of the proceeds from this offering to repay intercompany debt owed to Medtronic.
Despite double-digit revenue growth, MiniMed is currently reporting loss. The company aims to drive profitability by generating more revenue per customer than its competitors using its comprehensive offerings.
Commercially and operationally, MiniMed’s scaled global infrastructure creates a significant barrier to entry. Moreover, robust global user base of 640K entails recurring revenue generation opportunity through selling compatible consumable products.


MiniMed Group Pre-IPO: Broad Portfolio and Global Scale to Drive Profitability

Equity Bottom-Up

<ul><li>MiniMed Group, Inc ., the diabetes business being separated from Medtronic, has filed to go public in an offering that could raise approximately $728 million .</li><li>The company plans to offer 28,000,000 shares at a proposed price range of $25.00 to $28.00 per share and intends to list on the Nasdaq Global Select Market under the ticker “MMED.” At the midpoint price of $26.50 and based on approximately 280.8 million shares expected to be outstanding following the offering, MiniMed would carry an implied market capitalization of roughly $7.4 billion.</li><li>Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are leading the deal.</li></ul>

MiniMed Group, Inc ., the diabetes business being separated from Medtronic, has filed to go public in an offering that could raise approximately $728 million .The company plans to offer 28,000,000 shares at a proposed price range of $25.00 to $28.00 per share and intends to list on the Nasdaq Global Select Market under the ticker “MMED.” At the midpoint price of $26.50 and based on approximately 280.8 million shares expected to be outstanding following the offering, MiniMed would carry an implied market capitalization of roughly $7.4 billion.Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are leading the deal.

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>MiniMed seeks up to $7.9B valuation, offering 28M primary shares at $25–$28, with trading expected Friday (3/6).</li>
<li>Only fully integrated Smart Dosing platform; flagship 780G and expanding pipeline support differentiation and long-term growth.</li>
<li>FY2025 sales of $2.72B with recent double-digit growth; ~$712M net proceeds to fund cash retention and repay Medtronic debt.</li>
</ul>


MiniMed seeks up to $7.9B valuation, offering 28M primary shares at $25–$28, with trading expected Friday (3/6).
Only fully integrated Smart Dosing platform; flagship 780G and expanding pipeline support differentiation and long-term growth.
FY2025 sales of $2.72B with recent double-digit growth; ~$712M net proceeds to fund cash retention and repay Medtronic debt.


MiniMed Group, Inc. (MMED): Long-Awaited Medtronic Diabetes Spin-Off Sets Terms for IPO

<ul>
<li>Medtronic spinoff with $2.7B FY2025 revenue, global footprint, and blue-chip underwriters targeting a potential Q1 IPO.</li>
<li>Only fully integrated Smart Dosing ecosystem, strengthening competitive moat and positioning the story well for public-market investors.</li>
<li>Exposure to a $18B+ diabetes market growing 10%+ CAGR, with next-generation AID launches supporting an attractive Q1 IPO thesis.</li>
</ul>


Medtronic spinoff with $2.7B FY2025 revenue, global footprint, and blue-chip underwriters targeting a potential Q1 IPO.
Only fully integrated Smart Dosing ecosystem, strengthening competitive moat and positioning the story well for public-market investors.
Exposure to a $18B+ diabetes market growing 10%+ CAGR, with next-generation AID launches supporting an attractive Q1 IPO thesis.


MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

United States

MiniMed Group, Inc. is a medical technology company. The Company develops, manufactures, and markets smart insulin pen, injection port, therapy management, and insulin pump systems for diabetic patients. MiniMed Group operates globally.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

MiniMed Group (MMED US)

IPO Rating: MiniMed Group, Inc.

✅ IPO PROPHET RATING: 8.1/10 🏦 Deal Quality & Underwriters: 9/10 MiniMed Group is set to list on the Nasdaq under the symbol MMED, offering...

IPO Prophet

MiniMed Group Pre-IPO: Broad Portfolio and Global Scale to Drive Profitability

MiniMed has launched IPO consisting of 28M shares at a price range of $25–28 per share, thereby planning to raise $784M. Potential valuation of the...

Tina Banerjee

MiniMed Group Launches IPO

MiniMed Group, Inc ., the diabetes business being separated from Medtronic, has filed to go public in an offering that could raise approximately...

IPO Prophet

MiniMed Group, Inc. (MMED): Long-Awaited Medtronic Diabetes Spin-Off Sets Terms for IPO

MiniMed aims for a $7.9B valuation through a primary share offering, highlighting their Smart Dosing platform and strong sales growth projections.

IPO Boutique

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

IPO Rating: MiniMed Group, Inc.

✅ IPO PROPHET RATING: 8.1/10 🏦 Deal Quality & Underwriters: 9/10 MiniMed Group is set to list on the Nasdaq under the symbol MMED, offering...

IPO Prophet

MiniMed Group Pre-IPO: Broad Portfolio and Global Scale to Drive Profitability

MiniMed has launched IPO consisting of 28M shares at a price range of $25–28 per share, thereby planning to raise $784M. Potential valuation of the...

Tina Banerjee

MiniMed Group Launches IPO

MiniMed Group, Inc ., the diabetes business being separated from Medtronic, has filed to go public in an offering that could raise approximately...

IPO Prophet

MiniMed Group, Inc. (MMED): Long-Awaited Medtronic Diabetes Spin-Off Sets Terms for IPO

​MiniMed aims for a $7.9B valuation through a primary share offering, highlighting their Smart Dosing platform and strong sales growth projections.

IPO Boutique

MiniMed Group, Inc. (MMED): Peeking at the IPO Prospectus of Medtronic's Diabetes Spin-Off

​Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.

IPO Boutique

MiniMed aims for a $7.9B valuation through a primary share offering, highlighting their Smart Dosing platform and strong sales growth projections.

Medtronic spinoff poised for Q1 IPO with $2.7B revenue, global presence, and innovative Smart Dosing ecosystem targeting the growing diabetes market.